Cardiac Biotech Solutions EBITDA 2023-2024 | CBSC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cardiac Biotech Solutions ebitda from 2023 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cardiac Biotech Solutions ebitda from 2023 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$248.3B
Amgen (AMGN)	$155.9B
Gilead Sciences (GILD)	$142.4B
Vertex Pharmaceuticals (VRTX)	$99.3B
Bristol Myers Squibb (BMY)	$96.1B
GSK (GSK)	$81.1B
CSL (CSLLY)	$67.7B
Regeneron Pharmaceuticals (REGN)	$62.3B
Alnylam Pharmaceuticals (ALNY)	$59.1B
Argenex SE (ARGX)	$43.3B
Insmed (INSM)	$27.9B
BioNTech SE (BNTX)	$25.2B
Royalty Pharma (RPRX)	$21B
Biogen (BIIB)	$20B
Incyte (INCY)	$16.4B
Genmab (GNMSF)	$16B
Genmab (GMAB)	$15.7B
Illumina (ILMN)	$15.2B
Ascendis Pharma (ASND)	$12B
BioMarin Pharmaceutical (BMRN)	$11B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
QIAGEN (QGEN)	$10.9B
Exelixis (EXEL)	$10.3B
Moderna (MRNA)	$9.6B
Verona Pharma American Depositary Share (VRNA)	$9.1B
Bio-Techne Corp (TECH)	$8.9B
Exact Sciences (EXAS)	$8.7B
Halozyme Therapeutics (HALO)	$8.5B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$8.1B